top of page

ORTHOBIOLOGICS DIGEST™ NO. 11 The Medical Singularity: Can We Help Patients Keep Their Ankles Longer and foster Ankle Preservation?

Deborah Westergaard, M.D.
6 days ago
9 min read

Ankle preservation and The Medical Singularity: futuristic visualization of ankle anatomy, artificial intelligence, and regenerative medicine

REGEN EXPERTS / ORTHOBIOLOGICS DIGESTTM NO. 11

Deborah Westergaard, M.D. • Dallas and Plano, Texas • November 16, 2026


LEAD EDITORIAL

The Medical Singularity: Could We

Choose How Young We Stay?


Deborah Westergaard, M.D. | Medical Director, Regen Experts


What do people mean when they talk about the singularity? Imagine that we build an

artificial intelligence capable of designing a more capable one. That system designs the next,

and each generation improves faster than the last. The technological singularity is the

hypothetical turning point when that cycle moves so quickly we can no longer reliably

predict what happens next.

In longevity science there’s a related idea called longevity escape velocity. Imagine

celebrating a birthday after a year in which medical advances added more than a year to

your expected remaining lifespan. You would reach this birthday with more time ahead

than you had at your last. Could we someday also choose how young we stay?

When I speak of the Medical Singularity, I imagine a point when medicine can repair and

renew every tissue in the human body well enough that we could choose how biologically

young we wish to remain, and for how long. That is my definition. We would still have

birthdays. The question is whether aging itself would still set the limit on how long we could

live.

What makes that idea so ambitious is the word “every.” Suppose we restored the cartilage

in a woman’s knee so well that at eighty she could walk the trail she loved at forty. What if

she could no longer see the trail clearly or remember how to find her way home? Giving her

a genuine choice would require us to understand how to preserve the whole person.

Forty-one years after graduating from medical school, I still pause when I hear the word

“irreversible.” How do we know when a tissue has lost its capacity to recover? How often

does that word describe the limits of what we know how to do today? An AI might help us

recognize why one person’s tissues remain healthy while another’s begin to fail.

Researchers could then test whether acting on that knowledge preserves something a

patient can feel, use and depend on.

The ankle study that follows asks a version of that question we can study today. How much

longer might someone keep her own ankle before facing fusion or replacement? A patient

can tell me exactly what she would like to do with that time.


Source links

Vernor Vinge on the technological singularity


Aubrey de Grey on longevity escape velocity

BOOTSTRAPPING OUR WAY TO AN AGELESS FUTURE | Edge.org




ANKLE PRESERVATION

Can Bone Marrow Concentrate Help

Delay Ankle Fusion or Replacement?


Intraosseous Bone Marrow Concentrate and Long-Term Procedure-Free Survival in Bilateral

Non-Traumatic Ankle Osteoarthritis: A Contralateral-Controlled Study


Dr. Philippe Hernigou, Dr. Christopher Centeno, Matt Murphy, PhD, and colleagues studied

88 people with arthritis in both ankles. One ankle received the patient’s own bone marrow

concentrate injected into the bone beneath the joint surface. The other received nonsurgical

care tailored to symptoms. Comparing two ankles in one person accounts for age, genetics

and much of that person’s medical history.

During follow-up of up to 15 years, 16 of 88 treated ankles underwent fusion or

replacement, compared with 44 of 88 comparison ankles. Within that 15-year window, the

estimated average time free of either operation was 14.23 years for treated ankles and

10.77 years for comparison ankles, a difference of about three and a half years.

Participants averaged about 41 years of age. All had nontraumatic arthritis, and 60 had

osteonecrosis of the talus, meaning part of the bone supporting the joint had died. The

treated ankle was generally more painful and more advanced on X-ray. This was a

retrospective study with no random assignment. Its results cannot predict how much time

an individual patient might gain, particularly someone whose arthritis followed an ankle

fracture. This is key research supporting ankle preservation.

Source links

Hernigou and colleagues • original ankle study


My Take-Dr. Westergaard

When a patient tells me she has “bone-on-bone” arthritis, she is usually telling me what she

has heard about her cartilage. I also want to know what is happening in the bone carrying

her weight. I’ve been very pleased with the results I’ve seen after intraosseous procedures

in other joints. I’m grateful to Dr. Hernigou, Dr. Centeno and Matt Murphy, PhD. Their work

has changed the way I practice and made a difference in the lives of patients I care for.

I think we underestimate how much a painful foot or ankle can take out of someone’s day. A

patient who says, “I can still walk,” may have quietly given up her evening walk with a

friend because she can’t keep pace. I like to ask, “Where would you go if walking were

easier?” Her answer tells me what mobility means to her. Being able to go where you want,

with the people you love, is part of what makes those years healthy.

Forty-one years after graduating from medical school, that’s why I still practice. Helping

people stay mobile and enjoy their lives is my bliss.


Sources for My Take


Framingham Foot Study • foot pain and mobility


METABOLIC HEALTH AND KNEE ARTHRITIS Can a Weight-Loss Drug Ease Knee Arthritis Pain?


Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity Thomas Schnitzer, MD, PhD, and colleagues reported two randomized phase 3 trials of retatrutide, an investigational weekly injection that acts on three hormone receptors. The Lilly-funded trials enrolled adults with painful knee arthritis, a body mass index of at least 27, and no diabetes. Participants received retatrutide or placebo. In the 68-week trial, average pain on a ten-point scale fell by 4.3 points with 9 mg, 4.0 points with 12 mg and 2.6 points with placebo in the intention-to-treat analysis. Participants assigned retatrutide lost an average of 20% to 24% of body weight, compared with about 5% on placebo. A second trial found a similar pattern at 80 weeks. Participants reported better physical function. Gastrointestinal symptoms were common. Whether treatment preserved cartilage or delayed replacement remains open.


Source links

Retatrutide trials • original paper


My Take - Dr. Westergaard

Several patients first came to see me about their knees just as they were starting a GLP-1 medication. As they lost weight, I treated the subchondral bone beneath the joint surface with intraosseous bone marrow concentrate and addressed the soft tissues involved in their pain. I’ve been delighted with the results I’ve seen. Because these things happened together, I can’t say how much each contributed. What made the knees in this study hurt less? Gait research suggests that losing five pounds can take about twenty pounds of compressive force off the knee with each step. Fat tissue also releases inflammatory signals. A blood marker of inflammation, high-sensitivity C-reactive protein, fell during treatment, but it was measured only at the beginning and end. We don’t know whether that change preceded the pain relief. I’d like to see how fasting glucose and hemoglobin A1c tracked with pain over time. Human tissue studies link higher A1c with more inflammation in the knee lining. I also wish the investigators had followed the gut microbiome. In the Rotterdam Study, more Streptococcus in stool was associated with greater knee pain and, in an MRI subgroup, more joint fluid. Among people who lost similar amounts of weight, did those whose glucose control improved more, or whose gut microbes shifted, also find it easier to walk?


Sources for My Take


TRIUMPH design and glycemic assessments https://pmc.ncbi.nlm.nih.gov/articles/PMC12673447


Knee load per step


Walking and OA progression


A1c and synovitis


A1c and inflammatory signaling


Glucose and synovial cells


Rotterdam microbiome study


Subchondral knee BMC research




Can Gene Therapy Change Inflammation Inside an Arthritic Knee?


Safety, biodistribution, and exploratory clinical outcomes of a novel intra-articular IL-1Ra gene therapy (PCRX-201) in moderate-to-severe knee osteoarthritis: 2-year results of a phase 1 study What if a knee could make more of its own anti-inflammatory protein when inflammation flares? Dallas rheumatologist Stanley Cohen, MD, of Metroplex Clinical Research Center and colleagues investigated that idea in 72 people with moderate-to-severe knee osteoarthritis. The team published its two-year findings in Annals of the Rheumatic Diseases and presented a follow-up analysis at the American College of Rheumatology meeting in November. Gene therapy uses genetic material to change how cells work. Here, a single injection of an investigational treatment called PCRX-201 (enekinragene inzadenovec) carried instructions into joint cells for making interleukin-1 receptor antagonist, or IL-1Ra. This naturally occurring protein occupies the receptor where interleukin-1 would otherwise deliver an inflammatory signal. The treatment is designed to increase local production of the blocker when inflammation rises. Safety was the main question. All 72 participants received gene therapy. In a second group of 36, investigators also injected methylprednisolone immediately beforehand. Temporary knee effusion, a buildup of fluid, was the most common treatment-related problem. It occurred in 22 of 36 people who received gene therapy alone and 13 of 36 who also received steroid. The groups were enrolled sequentially, so we cannot be sure the steroid explains the difference. At two years, participants still being followed reported improvements in pain, stiffness and function. By then, 33 of the original 72 had discontinued. There was no placebo group. Those details matter when a patient asks how likely one injection is to help her for two years.


Source links Cohen and colleagues • two-year phase 1 paper https://pubmed.ncbi.nlm.nih.gov/42552219


My Take-Dr. Westergaard

Every new therapy needs a first step. I appreciate a study that starts with a focused question about one biological pathway. IL-1 signaling may matter quite a bit to someone whose inflamed knee hurts every time she stands. I’d like to know how much addressing that pathway helps and for how long. When I evaluate that same knee, I also examine the subchondral bone, menisci, tendons, ligaments and muscles. Which structures are contributing to this person’s pain? Which are limiting what she can do? Those answers guide what needs attention. A placebo-controlled trial with more complete follow-up would help us judge where this treatment might fit. Whether it preserves the joint remains a question for future research.


Sources for My Take

ACR 2026 • 104-week follow-up analysis


THE MEDICAL SINGULARITY IN THE SPINE

Can an Aging Spinal Disc Recover Some of Its Youthful Function?


How Billionaires Are Reverse Aging (TETR interview) Reprogramming to restore youthful epigenetics of senescent nucleus pulposus cells for mitigating intervertebral disc degeneration and alleviating low back pain David Sinclair’s TETR interview raises a question that follows me into the office. When we tell a patient her disc is degenerating, how much do we know about the tissue’s capacity to recover? A separate 2025 study by Ma and colleagues in Bone Research gives us an experimental way to ask that question. The interview provides the context. The findings below come from the paper. The nucleus pulposus is the water-rich center of a spinal disc. Its cells maintain the material that helps the disc bear load. The investigators explored partial cellular reprogramming, an attempt to restore some youthful patterns of cell activity while retaining the cell’s specialized identity. In rats with experimentally induced disc degeneration, treated discs showed better-preserved height, hydration and internal structure. Did those changes matter to the animals? The answer depended on the test. Treated rats tolerated more pressure applied over the lower back. Hind-paw withdrawal responses to touch and heat showed no statistically significant differences between groups. Local pressure sensitivity is a more precise description of the finding than a general claim that the treatment relieved back and leg pain.


Source links David Sinclair • TETR interview at 24:14


Ma and colleagues • original rat disc study


My Take- Dr. Westergaard

As a spine physician, I’m interested when both the disc and a measure of local tenderness improve. But a rat usually walks on four legs. For the patient sitting across from me, the question is whether her disc could tolerate years of upright loading and whether she could stand through a family gathering or walk farther with less pain. A naturally aging primate disc raises another question. Baboons and macaques develop disc degeneration and spend time upright, although they usually walk on all fours. I would like to know what happens in a disc that ages naturally. I also find it upsetting to think about an animal experiencing pain so that we can learn to relieve it in our patients. I look forward to the day when researchers can use AI to model a disc, simulate years of loading and test how it might respond to treatment. I’d want to know how well those predictions hold up against human tissue and, ultimately, what patients tell us they can feel

and do. That is another reason the Medical Singularity matters to me. I hope it changes how we make discoveries as well as what we can do for patients.


Sources for My Take

Animal models of disc degeneration • comparative review https://pmc.ncbi.nlm.nih.gov/articles/PMC4893450/



Frequently asked questions

1. What is ankle preservation?

Ankle preservation refers to treatments intended to maintain the natural ankle joint, relieve symptoms, preserve mobility, and potentially postpone more invasive surgery when clinically appropriate.

2. Can PRP help ankle osteoarthritis?

Platelet-rich plasma has been investigated for ankle osteoarthritis, but clinical evidence remains limited and mixed. A major placebo-controlled trial did not demonstrate a significant benefit over saline injections at 26 weeks.

3. Can bone marrow concentrate help preserve an arthritic ankle?

Bone marrow concentrate contains a mixture of cells and signaling molecules being investigated for musculoskeletal applications. Evidence specifically supporting BMC for ankle osteoarthritis remains preliminary, and durable structural preservation has not been established.

4. Can orthobiologics delay ankle replacement or fusion?

It is possible that symptom improvement could help selected patients defer surgery, but reliable evidence that PRP or BMC delays ankle replacement or fusion is currently insufficient.

5. How could artificial intelligence improve ankle preservation?

AI may eventually help combine imaging, clinical findings, biomechanics, and molecular data to improve patient selection, identify disease mechanisms, and predict treatment responses. These applications require clinical validation.

6. What does The Medical Singularity mean for ankle arthritis?

The Medical Singularity describes the potential convergence of artificial intelligence, regenerative biology, precision medicine, and other technologies to create more individualized approaches to disease and tissue degeneration.



Deborah Westergaard, M.D. • Dallas and Plano, Texas • November 16 2026

Comments


COSTS & COVERAGE

What will treatment cost?

A joint is a working system of cartilage, bone, ligaments, tendons, and supporting muscles. Your plan may include an injection into the joint space and targeted treatment of other tissues contributing to pain or dysfunction. Dr. Westergaard selects the orthobiologic, concentration, and dose for each appropriate target, considering the tissue involved, severity of the condition, your age, and clinical findings. Your estimate reflects the scope of your recommended care. Your evaluation is billed separately, and you receive an individualized written procedure estimate before scheduling.

​

​Orthobiologic procedures are generally not covered by traditional insurance. Regenexx employer benefits may cover eligible treatment, depending on your plan. CareCredit is available, subject to credit approval.

bottom of page